Shigella vaccine development: Prospective animal models and current status

Current Pharmaceutical Biotechnology

Volumn 14, Issue 10, 2013, Pages 903-912

  Kim, Yeon Jeong ^a   Yeo, Sang Gu ^b,c   Park, Jae Hak ^c   Ko, Hyun Jeong ^d  

^a Inje University   (South Korea)

^b Korea Centers for Disease Control and Prevention   (South Korea)

^c Seoul National University   (South Korea)

^d Kangwon National University   (South Korea)

Author keywords

Animal model; Immune modulation; Shigella vaccine; Shigellosis; Vaccine candidate; Vaccine efficacy

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIVE VACCINE; OUTER MEMBRANE PROTEIN; SHIGELLA VACCINE; STRESS ACTIVATED PROTEIN KINASE; SUBUNIT VACCINE;

CELL FUNCTION; CELL SURVIVAL; COLONY FORMING UNIT; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; MEMBRANE VESICLE; MORTALITY; NONHUMAN; REVIEW; SHIGELLA; SHIGELLOSIS; VACCINE PRODUCTION;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DYSENTERY, BACILLARY; HUMANS; MICE; SHIGELLA; SHIGELLA VACCINES; VACCINES, ATTENUATED; VACCINES, CONJUGATE; VACCINES, INACTIVATED; VACCINES, SUBUNIT;

EID: 84896714320     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201014666131226123900     Document Type: Review

References (112)

1. Hale, T.L. Genetic basis of virulence in Shigella species. Microbiol. Rev., 1991, 55(2), 206-2024.
2. Chang, Z.; Lu, S.; Chen, L.; Jin, Q.; Yang, J., Causative species and serotypes of shigellosis in mainland China: Systematic review and meta-analysis. PLoS One, 2012, 7(12), e52515.
3. Niyogi, S. K. Shigellosis. J. Microbiol., 2005, 43(2), 133-1343.
4. Kotloff, K.L.; Winickoff, J.P.; Ivanoff, B.; Clemens, J.D.; Swerdlow, D.L.; Sansonetti, P.J.; Adak, G.K.; Levine, M.M. Global burden of Shigella infections: Implications for Vaccine, development and implementation of control strategies. Bull. World Health Organ., 1999, 77(8), 651-666.
5. Gu, B.; Ke, X.; Pan, S.; Cao, Y.; Zhuang, L.; Yu, R.; Qian, H.; Liu, G.; Tong, M. Prevalence and trends of aminoglycoside resistance in Shigella worldwide, 1999-2010. J. Biomed. Res., 2013, 27(2), 103-115.
6. Shen, Y.; Qian, H.; Gong, J.; Deng, F.; Dong, C.; Zhou, L.; Guo, H. High prevalence of antibiotic resistance and molecular characterization of integrons among Shigella isolates in Eastern China. Antimicrob. Agents Chemother., 2013, 57(3), 1549-1551.
7. Mandal, J. V. G.; Emelda, J. S. M.; Parija, S. C. The recent trends of shigellosis: A JIPMER perspective. J. Clin. Diagn Res., 2012, 6(9), 1474-1477.
8. Pu, X. Y.; Zhang, Q.; Pan, J. C.; Shen, Z.; Zhang, W. Spontaneous mutation frequency and molecular mechanisms of Shigella flexneri fluoroquinolone resistance under antibiotic selective stress. World J. Microbiol. Biotechnol., 2013, 29(2), 365-371.
9. Qiu, S.; Xu, X.; Wang, Y.; Yang, G.; Wang, Z.; Wang, H.; Zhang, L.; Liu, N.; Chen, C.; Liu, W.; Li, J.; Su, W.; Jia, L.; Wang, L.; Jin, H.; Keim, P.; Yuan, Z.; Huang, L.; Song, H. Emergence of resistance to fluoroquinolones and third-generation cephalosporins in Shigella flexneri subserotype 1c isolates from China. Clin. Microbiol. Infect., 2012, 18(4), E95-E98.
10. Qiu, S.; Wang, Y.; Xu, X.; Li, P.; Hao, R.; Yang, C.; Liu, N.; Li, Z.; Wang, Z.; Wang, J.; Wu, Z.; Su, W.; Yang, G.; Jin, H.; Wang, L.; Sun, Y.; Yuan, Z.; Huang, L.; Song, H. Multidrug-resistant atypical variants of Shigella flexneri in China. Emerg. Infect. Dis., 2013, 19(7), 1147-1150.
11. Tariq, A.; Haque, A.; Ali, A.; Bashir, S.; Habeeb, M. A.; Salman, M.; Sarwar, Y. Molecular profiling of antimicrobial resistance and integron association of multidrug-resistant clinical isolates of Shigella species from Faisalabad, Pakistan. Can. J. Microbiol., 2012, 58(9), 1047-1054.
12. Barry, E.M.; Pasetti, M.F.; Sztein, M.B.; Fasano, A.; Kotloff, K.L.; Levine, M.M. Progress and pitfalls in Shigella Vaccine, research. Nat. Rev. Gastroenterol.Hepatol., 2013, 10(4), 245-255.
13. Phalipon, A.; Sansonetti, P. J. Shigella's ways of manipulating the host intestinal innate and adaptive immune system: A tool box for survival? Immunol. Cell Biol., 2007, 85(2), 119-129.
14. Telford, J.L.; Baldari, C.T., Shigella targets T cells. Cell Host Microbe, 2011, 9(4), 253-254.
15. Ashida, H.; Ogawa, M.; Mimuro, H.; Sasakawa, C. Shigella infection of intestinal epithelium and circumvention of the host innate defense system. Curr. Top Microbiol. Immunol., 2009, 337, 231-255.
16. Ogawa, M.; Handa, Y.; Ashida, H.; Suzuki, M.; Sasakawa, C. The versatility of Shigella effectors. Nat. Rev. Micro., 2008, 6(1), 11-16.
17. Camacho, A.I.; Irache, J.M.; Gamazo, C. Recent progress towards development of a Shigella vaccine. Exp. Rev. Vaccine, 2013, 12(1), 43-55.
18. Kweon, M.N. Shigellosis: The current status of vaccine, development. Curr. Opin. Infect. Dis., 2008, 21(3), 313-318.
19. Sansonetti, P.J. Shigellosis: An old disease in new clothes? PLoS Med., 2006, 3(9), e354.
20. Fernandez, M. I.; Thuizat, A.; Pedron, T.; Neutra, M.; Phalipon, A.; Sansonetti, P.J. A newborn mouse model for the study of intestinal pathogenesis of shigellosis. Cell Microbiol. 2003, 5(7), 481-491.
21. Sansonetti, P.J.; Arondel, J.; Cantey, J.R.; Prevost, M.C.; Huerre, M. Infection of rabbit Peyer's patches by Shigella flexneri: Effect of adhesive or invasive bacterial phenotypes on follicle-associated epithelium. Infect. Immun.,1996, 64(7), 2752-2764.
22. Sereny, B. Experimental shigella keratoconjunctivitis; a preliminary report. Acta Microbiol. Acad. Sci. Hung., 1955, 2(3), 293-296.
23. Shim, D.H.; Suzuki, T.; Chang, S.Y.; Park, S.M.; Sansonetti, P.J.; Sasakawa, C.; Kweon, M.N. New animal model of shigellosis in the Guinea pig: Its usefulness for protective efficacy studies. J. Immunol., 2007, 178(4), 2476-2482.
24. Heine, S.J.; Diaz-McNair, J.; Martinez-Becerra, F.J.; Choudhari, S.P.; Clements, J.D.; Picking, W.L.; Pasetti, M.F. Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD. Vaccine, 2013, 31(28), 2919-2929.
25. Pore, D.; Mahata, N.; Pal, A.; Chakrabarti, M.K. Outer membrane protein A(OmpA) of Shigella flexneri 2a, induces protective immune response in a mouse model. PLoS One, 2011, 6(7), e22663.
26. Camacho, A.I.; Irache, J.M.; de Souza, J.; Sánchez-Gómez, S.; Gamazo, C. Nanoparticle-based vaccine, for mucosal protection against Shigella flexneri in mice. Vaccine, 2013, 31(32), 3288-3294.
27. Shim, D.H.; Chang, S.Y.; Park, S.M.; Jang, H.; Carbis, R.; Czerkinsky, C.; Uematsu, S.; Akira, S.; Kweon, M.N. Immunogenicity and protective efficacy offered by a ribosomalbased Vaccine, from Shigella flexneri 2a. Vaccine, 2007, 25(25), 4828-4836.
28. Voino-Yasenetsky, M.V.; Voino-Yasenetskaya, M.K. Experimental pneumonia caused by bacteria of the Shigella group. Acta Morphol. Acad. Sci. Hung, 1962, 11, 439-454.
29. Fernandez, M.I.; Thuizat, A.; Pedron, T.; Neutra, M.; Phalipon, A.; Sansonetti, P.J. A newborn mouse model for the study of intestinal pathogenesis of shigellosis. Cell Microb., 2003, 5(7), 481-491.
30. Chang, S.Y.; Lee, S.N.; Yang, J.Y.; Kim, D.W.; Yoon, J.H.; Ko, H.J.; Ogawa, M.; Sasakawa, C.; Kweon, M.N. Autophagy controls an intrinsic host defense to bacteria by promoting epithelial cell survival: a murine model. PloS One, 2013, 8(11), e81095.
31. Arm, H. G.; Floyd, T.M.; Faber, J.E.; Hayes, J.R. Use of ligated segments of rabbit small intestine in experimental shigellosis. J. Bacteriol., 1965, 89, 803-89.
32. Canning, B.J.; Chou, Y. Using guinea pigs in studies relevant to asthma and COPD. Pulmon. Pharmacol. Therapeut., 2008, 21(5), 702-720.
33. Shipley, S.T.; Panda, A.; Khan, A.Q.; Kriel, E. H.; Maciel, M., Jr.; Livio, S.; Nataro, J.P.; Levine, M.M.; Sztein, M.B.; DeTolla, L.J., A challenge model for Shigella dysenteriae 1 in cynomolgus monkeys(Macaca fascicularis). Comp. Med., 2010, 60(1), 54-61.
34. Bodhidatta, L.; Pitisuttithum, P.; Chamnanchanant, S.; Chang, K.T.; Islam, D.; Bussaratid, V.; Venkatesan, M.M.; Hale, T.L.; Mason, C. J., Establishment of a Shigella sonnei human challenge model in Thailand. Vaccine, 2012, 30(49), 7040-7045.
35. Herrington, D.A.; Van de Verg, L.; Formal, S.B.; Hale, T.L.; Tall, B.D.; Cryz, S.J.; Tramont, E.C.; Levine, M.M. Studies in volunteers to evaluate candidate Shigella Vaccines: Further experience with a bivalent Salmonella typhi-Shigella sonnei Vaccine, and protection conferred by previous Shigella sonnei disease. Vaccine, 1990, 8(4), 353-357.
36. Mc, G.C.; Floyd, T.M. Studies on experimental shigellosis. I. Shigella infections of normal mice. J. Exper. Med., 1958, 108(2), 269-276.
37. Sansonetti, P.J.; Tran Van Nhieu, G.; Egile, C. Rupture of the intestinal epithelial barrier and mucosal invasion by Shigella flexneri. Clin. Infect. Dis., 1999, 28(3), 466-475.
38. Zychlinsky, A.; Prevost, M.C.; Sansonetti, P.J. Shigella flexneri induces apoptosis in infected macrophages. Nature, 1992, 358(6382), 167-916.
39. Senerovic, L.; Tsunoda, S.P.; Goosmann, C.; Brinkmann, V.; Zychlinsky, A.; Meissner, F.; Kolbe, M. Spontaneous formation of IpaB ion channels in host cell membranes reveals how Shigella induces pyroptosis in macrophages. Cell Death Dis., 2012, 3, e384.
40. Mounier, J.; Boncompain, G.; Senerovic, L.; Lagache, T.; Chretien, F.; Perez, F.; Kolbe, M.; Olivo-Marin, J.C.; Sansonetti, P.J.; Sauvonnet, N. Shigella effector IpaB-induced cholesterol relocation disrupts the Golgi complex and recycling network to inhibit host cell secretion. Cell Host Microbe, 2012, 12(3), 381-389.
41. Marquart, M.E.; Picking, W.L.; Picking, W.D. Soluble invasion plasmid antigen C(IpaC) from Shigella flexneri elicits epithelial cell responses related to pathogen invasion. Infect. Immun., 1996, 64(10), 4182-7.
42. Shaikh, N.; Terajima, J.; Watanabe, H. IpaC of Shigella binds to the C-terminal domain of beta-catenin. Microb. Pathog., 2003, 35(3), 107-117.
43. Kueltzo, L.A.; Osiecki, J.; Barker, J.; Picking, W.L.; Ersoy, B.; Picking, W. D.; Middaugh, C. R. Structure-function analysis of invasion plasmid antigen C(IpaC) from Shigella flexneri. J. Biol. Chem., 2003, 278(5), 2792-2798.
44. Terry, C.M.; Picking, W.L.; Birket, S.E.; Flentie, K.; Hoffman, B.M.; Barker, J.R.; Picking, W.D. The C-terminus of IpaC is required for effector activities related to Shigella invasion of host cells. Microb. Pathog., 2008, 45(4), 282-289.
45. Ashida, H.; Ogawa, M.; Kim, M.; Suzuki, S.; Sanada, T.; Punginelli, C.; Mimuro, H.; Sasakawa, C. Shigella deploy multiple countermeasures against host innate immune responses. Curr. Opin. Microbiol., 2011, 14(1), 16-23.
46. Chen, Y.; Smith, M. R.; Thirumalai, K.; Zychlinsky, A., A bacterial invasin induces macrophage apoptosis by binding directly to ICE. EMBO J., 1996, 15(15), 3853-3860.
47. Sansonetti, P.J.; Phalipon, A.; Arondel, J.; Thirumalai, K.; Banerjee, S.; Akira, S.; Takeda, K.; Zychlinsky, A., Caspase-1 activation of IL-1beta and IL-18 are essential for Shigella flexneriinduced inflammation. Immunity, 2000, 12(5), 581-590.
48. Willingham, S.B.; Bergstralh, D.T.; O'Connor, W.; Morrison, A. C.; Taxman, D.J.; Duncan, J.A.; Barnoy, S.; Venkatesan, M. M.; Flavell, R.A.; Deshmukh, M.; Hoffman, H.M.; Ting, J.P.Y. Microbial pathogen-induced necrotic cell death mediated by the inflammasome components CIAS1/Cryopyrin/NLRP3 and ASC. Cell Host Microbe, 2007, 2(3), 147-159.
49. Girardin, S.E.; Tournebize, R.; Mavris, M.; Page, A.-L.; Li, X.; Stark, G.R.; Bertin, J.; DiStefano, P.S.; Yaniv, M.; Sansonetti, P. J.; Philpott, D.J. CARD4/Nod1 mediates NF-[kappa]B and JNK activation by invasive Shigella flexneri. EMBO Rep., 2001, 2(8), 736-742.
50. Menning, M.; Kufer, T.A. A role for the Ankyrin repeat containing protein Ankrd17 in Nod1-and Nod2-mediated inflammatory responses. FEBS Letters, 2013, 587(14), 2137-2142.
51. Carayol, N.; Tran Van Nhieu, G. Tips and tricks about Shigella invasion of epithelial cells. Curr. Opin. Microbiol., 2013, 16(1), 32-37.
52. Pendaries, C.; Tronchere, H.; Arbibe, L.; Mounier, J.; Gozani, O.; Cantley, L.; Fry, M. J.; Gaits-Iacovoni, F.; Sansonetti, P.J.; Payrastre, B. PtdIns5P activates the host cell PI3-kinase/Akt pathway during Shigella flexneri infection. EMBO J., 2006, 25(5), 1024-1034.
53. Kim, D.W.; Lenzen, G.; Page, A.L.; Legrain, P.; Sansonetti, P.J.; Parsot, C. The Shigella flexneri effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes. Proc. Natl. Acad. Sci. USA, 2005, 102(39), 14046-14051.
54. Arbibe, L.; Kim, D.W.; Batsche, E.; Pedron, T.; Mateescu, B.; Muchardt, C.; Parsot, C.; Sansonetti, P.J. An injected bacterial effector targets chromatin access for transcription factor NFkappaB to alter transcription of host genes involved in immune responses. Nat. Immunol., 2007, 8(1), 47-56.
55. Sanada, T.; Kim, M.; Mimuro, H.; Suzuki, M.; Ogawa, M.; Oyama, A.; Ashida, H.; Kobayashi, T.; Koyama, T.; Nagai, S.; Shibata, Y.; Gohda, J.; Inoue, J.; Mizushima, T.; Sasakawa, C. The Shigella flexneri effector OspI deamidates UBC13 to dampen the inflammatory response. Nature, 2012, 483(7391), 623-626.
56. Sperandio, B.; Regnault, B.; Guo, J.; Zhang, Z.; Stanley, S.L., Jr.; Sansonetti, P. J.; Pedron, T. Virulent Shigella flexneri subverts the host innate immune response through manipulation of antimicrobial peptide gene expression. J. Exp. Med., 2008, 205(5), 1121-1132.
57. Salgado-Pabon, W.; Celli, S.; Arena, E.T.; Nothelfer, K.; Roux, P.; Sellge, G.; Frigimelica, E.; Bousso, P.; Sansonetti, P.J.; Phalipon, A. Shigella impairs T lymphocyte dynamics in vivo. Proc. Natl. Acad. Sci. USA, 2013, 110(12), 4458-4463.
58. Konradt, C.; Frigimelica, E.; Nothelfer, K.; Puhar, A.; Salgado-Pabon, W.; di Bartolo, V.; Scott-Algara, D.; Rodrigues, C.D.; Sansonetti, P. J.; Phalipon, A. The Shigella flexneri type three secretion system effector IpgD inhibits T cell migration by manipulating host phosphoinositide metabolism. Cell Host Microbe, 2011, 9(4), 263-272.
59. Ranallo, R.T.; Fonseka, C.P.; Cassels, F.; Srinivasan, J.; Venkatesan, M.M. Construction and characterization of bivalent Shigella flexneri 2a Vaccine, strains SC608(pCFAI) and SC608(pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli. Infect. Immun.,2005, 73(1), 258-267.
60. Rahman, K.M.; Arifeen, S.E.; Zaman, K.; Rahman, M.; Raqib, R.; Yunus, M.; Begum, N.; Islam, M.S.; Sohel, B.M.; Venkatesan, M.; Hale, T.L.; Isenbarger, D.W.; Sansonetti, P.J.; Black, R.E.; Baqui, A.H. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a Vaccine, candidate(SC602) among healthy adults and school children in Matlab, Bangladesh. Vaccine, 2011, 29(6), 1347-1354.
61. Kotloff, K.L.; Simon, J.K.; Pasetti, M.F.; Sztein, M.B.; Wooden, S.L.; Livio, S.; Nataro, J.P.; Blackwelder, W.C.; Barry, E.M.; Picking, W.; Levine, M.M. Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a Vaccine, grown on animal-free media. Human Vaccine, 2007, 3(6), 268-275.
62. Ranallo, R.T.; Fonseka, S.; Boren, T.L.; Bedford, L.A.; Kaminski, R.W.; Thakkar, S.; Venkatesan, M.M. Two live attenuated Shigella flexneri 2a strains WRSf2G12 and WRSf2G15: a new combination of gene deletions for 2nd generation live attenuated Vaccine, candidates. Vaccine, 2012, 30(34), 5159-5171.
63. Katz, D.E.; Coster, T.S.; Wolf, M.K.; Trespalacios, F.C.; Cohen, D.; Robins, G.; Hartman, A.B.; Venkatesan, M.M.; Taylor, D.N.; Hale, T.L. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a Vaccine,(SC602) and excretion of Vaccine, organisms in North American volunteers. Infect. Immun., 2004, 72(2), 923-930.
64. Launay, O.; Sadorge, C.; Jolly, N.; Poirier, B.; Bechet, S.; van der Vliet, D.; Seffer, V.; Fenner, N.; Dowling, K.; Giemza, R.; Johnson, J.; Ndiaye, A.; Vray, M.; Sansonetti, P.; Morand, P.; Poyart, C.; Lewis, D.; Gougeon, M.L. Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 Vaccine, in healthy volunteers: Results of a Phase 2, randomized, double-blind placebocontrolled trial. Vaccine, 2009, 27(8), 1184-1191.
65. McKenzie, R.; Venkatesan, M.M.; Wolf, M.K.; Islam, D.; Grahek, S.; Jones, A.M.; Bloom, A.; Taylor, D.N.; Hale, T.L.; Bourgeois, A. L., Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 Vaccine, candidate. Vaccine, 2008, 26(26), 3291-3296.
66. Sadorge, C.; Ndiaye, A.; Beveridge, N.; Frazer, S.; Giemza, R.; Jolly, N.; Johnson, J.; Liddy, H.; Cosgrove, C.A.; Allavena, P.; Mantovani, A.; Bechet, S.; Fontaine-Thompson, A.; Griffin, G.E.; Dupont, F.; Sansonetti, P.J.; Lewis, D.J. Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 DeltaicsA Deltaent Deltafep DeltastxA:HgR oral Vaccine, SC599 in healthy human adult volunteers. Vaccine, 2008, 26(7), 978-987.
67. Kotloff, K.L.; Taylor, D.N.; Sztein, M.B.; Wasserman, S.S.; Losonsky, G.A.; Nataro, J.P.; Venkatesan, M.; Hartman, A.; Picking, W.D.; Katz, D.E.; Campbell, J.D.; Levine, M.M.; Hale, T. L. Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral Vaccine, strain WRSS1 in healthy adults. Infect. Immunity, 2002, 70(4), 2016-2021.
68. Orr, N.; Katz, D.E.; Atsmon, J.; Radu, P.; Yavzori, M.; Halperin, T.; Sela, T.; Kayouf, R.; Klein, Z.; Ambar, R.; Cohen, D.; Wolf, M. K.; Venkatesan, M.M.; Hale, T.L. Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 Vaccine, in Israeli volunteers. Infect. Immun.,2005, 73(12), 8027-8032.
69. Yang, J.Y.; Lee, S.N.; Chang, S.Y.; Ko, H.J.; Ryu, S.; Kweon, M. N. A mouse model of shigellosis by intraperitoneal infection. J. Infect. Dis., 2013.
70. Walker, R.I., Considerations for development of whole cell bacterial Vaccine,s to prevent diarrheal diseases in children in developing countries. Vaccine, 2005, 23(26), 3369-3385.
71. McKenzie, R.; Walker, R.I.; Nabors, G.S.; Van De Verg, L.L.; Carpenter, C.; Gomes, G.; Forbes, E.; Tian, J.H.; Yang, H.H.; Pace, J.L.; Jackson, W.J.; Bourgeois, A.L. Safety and immunogenicity of an oral, inactivated, whole-cell Vaccine, for Shigella sonnei: preclinical studies and a Phase I trial. Vaccine, 2006, 24(18), 3735-3745.
72. Hartman, A.B.; Van De Verg, L.L.; Venkatesan, M.M. Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heatkilled Shigella Vaccine,s. Infect. Immun.,1999, 67(11), 5841-5847.
73. Mukhopadhaya, A.; Mahalanabis, D.; Khanam, J.; Chakrabarti, M. K. Protective efficacy of oral immunization with heat-killed Shigella flexneri 2a in animal model: Study of cross protection, immune response and antigenic recognition. Vaccine, 2003, 21(21-22), 3043-3050.
74. Cohen, D.; Ashkenazi, S.; Green, M.; Lerman, Y.; Slepon, R.; Robin, G.; Orr, N.; Taylor, D.N.; Sadoff, J.C.; Chu, C.; Shiloach, J.; Schneerson, R.; Robbins, J.B. Safety and immunogenicity of investigational Shigella conjugate Vaccine,s in Israeli volunteers. Infect. Immun.,1996, 64(10), 4074-4077.
75. Passwell, J.H.; Ashkenzi, S.; Banet-Levi, Y.; Ramon-Saraf, R.; Farzam, N.; Lerner-Geva, L.; Even-Nir, H.; Yerushalmi, B.; Chu, C.; Shiloach, J.; Robbins, J.B.; Schneerson, R. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine, 2010, 28(10), 2231-2235.
76. Cohen, D.; Ashkenazi, S.; Green, M.; Gdalevich, M.; Yavzori, M.; Orr, N.; Robin, G.; Slepon, R.; Lerman, Y.; Block, C.; Ashkenazi, I.; Taylor, D.; Hale, L.; Sadoff, J.; Schneerson, R.; Robbins, J.; Wiener, M.; Shemer, J. Clinical trials of Shigella Vaccine,s in Israel. Adv. Exp. Med. Biol., 1996, 397, 159-167.
77. Chu, C.Y.; Liu, B.K.; Watson, D.; Szu, S.S.; Bryla, D.; Shiloach, J.; Schneerson, R.; Robbins, J.B. Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1(Shiga's bacillus) bound to tetanus toxoid. Infect. Immun.,1991, 59(12), 4450-4458.
78. Cohen, D.; Ashkenazi, S.; Green, M.S.; Gdalevich, M.; Robin, G.; Slepon, R.; Yavzori, M.; Orr, N.; Block, C.; Ashkenazi, I.; Shemer, J.; Taylor, D.N.; Hale, T.L.; Sadoff, J.C.; Pavliakova, D.; Schneerson, R.; Robbins, J.B. Double-blind vaccine,-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine, in young adults. Lancet, 1997, 349(9046), 155-159.
79. Ashkenazi, S.; Passwell, J.H.; Harlev, E.; Miron, D.; Dagan, R.; Farzan, N.; Ramon, R.; Majadly, F.; Bryla, D.A.; Karpas, A.B.; Robbins, J.B.; Schneerson, R. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. The J. Infect. Dis., 1999, 179(6), 1565-1568.
80. Chowers, Y.; Kirschner, J.; Keller, N.; Barshack, I.; Bar-Meir, S.; Ashkenazi, S.; Schneerson, R.; Robbins, J.; Passwell, J. H. Ospecific [corrected] polysaccharide conjugate Vaccine,-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(7), 2396-401.
81. Turbyfill, K.R.; Hartman, A.B.; Oaks, E.V. Isolation and characterization of a Shigella flexneri invasin complex subunit Vaccine,. Infect. Immun., 2000, 68(12), 6624-32.
82. Park, H.; Valencia-Gallardo, C.; Sharff, A.; Tran Van Nhieu, G.; Izard, T. Novel vinculin binding site of the IpaA invasin of Shigella. J Biol Chem 2011, 286(26), 23214-21.
83. Shen, D.K.; Saurya, S.; Wagner, C.; Nishioka, H.; Blocker, A.J. Domains of the Shigella flexneri type III secretion system IpaB protein involved in secretion regulation. Infect. Immun., 2010, 78(12), 4999-5010.
84. Tran Van Nhieu, G.; Bourdet-Sicard, R.; Dumenil, G.; Blocker, A.; Sansonetti, P.J. Bacterial signals and cell responses during Shigella entry into epithelial cells. Cell Microbiol., 2000, 2(3), 187-93.
85. Picking, W.L.; Nishioka, H.; Hearn, P.D.; Baxter, M.A.; Harrington, A.T.; Blocker, A.; Picking, W.D. IpaD of Shigella flexneri is independently required for regulation of Ipa protein secretion and efficient insertion of IpaB and IpaC into host membranes. Infect. Immun., 2005, 73(3), 1432-40.
86. Espina, M.; Olive, A.J.; Kenjale, R.; Moore, D.S.; Ausar, S.F.; Kaminski, R.W.; Oaks, E.V.; Middaugh, C.R.; Picking, W.D.; Picking, W.L. IpaD localizes to the tip of the type III secretion system needle of Shigella flexneri. Infect. Immun., 2006, 74(8), 4391-400.
87. Barzu, S.; Nato, F.; Rouyre, S.; Mazie, J.C.; Sansonetti, P.; Phalipon, A. Characterization of B-cell epitopes on IpaB, an invasion-associated antigen of Shigella flexneri: Identification of an immunodominant domain recognized during natural infection. Infect. Immun., 1993, 61(9), 3825-31.
88. Oaks, E.V.; Hale, T.L.; Formal, S.B. Serum immune response to Shigella protein antigens in rhesus monkeys and humans infected with Shigella spp. Infect. Immun., 1986, 53(1), 57-63.
89. Martinez-Becerra, F.J.; Kissmann, J.M.; Diaz-McNair, J.; Choudhari, S.P.; Quick, A.M.; Mellado-Sanchez, G.; Clements, J.D.; Pasetti, M.F.; Picking, W.L. Broadly protective Shigella Vaccine, based on type III secretion apparatus proteins. Infect. Immun., 2012, 80(3), 1222-31.
90. Turbyfill, K.R.; Joseph, S.W.; Oaks, E.V. Recognition of three epitopic regions on invasion plasmid antigen C by immune sera of rhesus monkeys infected with Shigella flexneri 2a. Infect. Immun., 1995, 63(10), 3927-35.
91. Kar, A.K.; Ghosh, A.S.; Chauhan, K.; Ahamed, J.; Basu, J.; Chakrabarti, P.; Kundu, M. Involvement of a 43-kilodalton outer membrane protein in beta-lactam resistance of Shigella dysenteriae. Antimicrob. Agents Chemother., 1997, 41(10), 2302-4.
92. Zhao, H.; Sequeira, R.D.; Galeva, N.A.; Tang, L. The host outer membrane proteins OmpA and OmpC are associated with the Shigella phage Sf6 virion. Virology, 2011, 409(2), 319-327.
93. Peng, X.; Ye, X.; Wang, S. Identification of novel immunogenic proteins of Shigella flexneri 2a by proteomic methodologies. Vaccine, 2004, 22(21-22), 2750-2756.
94. Ying, T.; Wang, H.; Li, M.; Wang, J.; Shi, Z.; Feng, E.; Liu, X.; Su, G.; Wei, K.; Zhang, X.; Huang, P.; Huang, L. Immunoproteomics of outer membrane proteins and extracellular proteins of Shigella flexneri 2a 2457T. Proteomics, 2005, 5(18), 4777-93.
95. Chakrabarti, S.; Sinha, A.K. Antibody response to outer membrane proteins in Shigella dysenteriae type 1 infection with special reference to appearance of murine antibodies. Indian J. Med. Res., 1996, 104, 142-7.
96. Roy, S.; Das, A.B.; Biswas, T. Antigenicity and antigenic relatedness of the outer membrane proteins of Shigella species. Microbios, 1994, 79(318), 55-64.
97. Pore, D.; Chakrabarti, M.K. Outer membrane protein A(OmpA) from Shigella flexneri 2a: A promising subunit vaccine, candidate. Vaccine, 2013,31(36), 3644-3650.
98. Pore, D.; Mahata, N.; Pal, A.; Chakrabarti, M.K. 34kDa MOMP of Shigella flexneri promotes TLR2 mediated macrophage activation with the engagement of NF-κB and p38 MAP kinase signaling. Molecul. Immunol., 2010, 47(9), 1739-1746.
99. Collins, B.S. Gram-negative outer membrane vesicles in vaccine, development. Discov. Med., 2011, 12(62), 7-15.
100. Mitra, S.; Barman, S.; Nag, D.; Sinha, R.; Saha, D.R.; Koley, H. Outer membrane vesicles of Shigella boydii type 4 induce passive immunity in neonatal mice.
101. Turbyfill, K.R.; Kaminski, R.W.; Oaks, E.V. Immunogenicity and efficacy of highly purified invasin complex Vaccine, from Shigella flexneri 2a. Vaccine, 2008, 26(10), 1353-1364.
102. Oaks, E.V.; Turbyfill, K.R. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex(Invaplex) Vaccine,. Vaccine, 2006, 24(13), 2290-2301.
103. Tribble, D.; Kaminski, R.; Cantrell, J.; Nelson, M.; Porter, C.; Baqar, S.; Williams, C.; Arora, R.; Saunders, J.; Ananthakrishnan, M.; Sanders, J.; Zaucha, G.; Turbyfill, R.; Oaks, E. Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal Vaccine, in adult volunteers. Vaccine, 2010, 28(37), 6076-6085.
104. Riddle, M.S.; Kaminski, R.W.; Williams, C.; Porter, C.; Baqar, S.; Kordis, A.; Gilliland, T.; Lapa, J.; Coughlin, M.; Soltis, C.; Jones, E.; Saunders, J.; Keiser, P. B.; Ranallo, R. T.; Gormley, R.; Nelson, M.; Turbyfill, K.R.; Tribble, D.; Oaks, E.V. Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 Vaccine,. Vaccine, 2011, 29(40), 7009-7019.
105. Kaminski, R.W.; Turbyfill, K.R.; Chao, C.; Ching, W.M.; Oaks, E. V. Mucosal adjuvanticity of a Shigella invasin complex with dnabased Vaccine,s. Clin. Vaccine Immunol., 2009, 16(4), 574-786.
106. Kaminski, R.W.; Turbyfill, K.R.; Oaks, E.V. Mucosal adjuvant properties of the Shigella invasin complex. Infect. Immun., 2006, 74(5), 2856-66.
107. Fries, L.F.; Montemarano, A.D.; Mallett, C.P.; Taylor, D.N.; Hale, T.L.; Lowell, G.H. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide Vaccine, administered intranasally to healthy adults. Infect. Immun., 2001, 69(7), 4545-4553.
108. Orr, N.; Robin, G.; Cohen, D.; Arnon, R.; Lowell, G.H. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide Vaccines in animal models. Infect. Immun., 1993, 61(6), 2390-2395.
109. Mallett, C.P.; Hale, T.L.; Kaminski, R.W.; Larsen, T.; Orr, N.; Cohen, D.; Lowell, G.H. Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide Vaccine,s protects against lethal pneumonia in a murine model of Shigella infection. Infect. Immun., 1995, 63(6), 2382-2386.
110. Barnoy, S.; Baqar, S.; Kaminski, R.W.; Collins, T.; Nemelka, K.; Hale, T.L.; Ranallo, R.T.; Venkatesan, M.M. Shigella sonnei Vaccine, candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested Vaccine, candidate, in a primate model of infection. Vaccine, 2011, 29(37), 6371-6378.
111. Dharmasena, M.N.; Hanisch, B.W.; Wai, T.T.; Kopecko, D.J. Stable expression of Shigella sonnei form I O-polysaccharide genes recombineered into the chromosome of live Salmonella oral vaccine, vector Ty21a. Int. J. Med. Microbiol., 2013, 303(3), 105-113.
112. Robbins, J.B.; Kubler-Kielb, J.; Vinogradov, E.; Mocca, C.; Pozsgay, V.; Shiloach, J.; Schneerson, R. Synthesis, characterization, and immunogenicity in mice of Shigella sonnei Ospecific oligosaccharide-core-protein conjugates. Proc. Natl. Acad. Sci. USA 2009, 106(19), 7974-7978.